Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -25.38% is 98% above its 4-year average of -1543.18%, near the high end of its 4-year range (-9279.32%–66.09%).
98.95% above its 12-month average of -2417.91%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2024 (2024-06-30): 66.09%.
EBITDA MARGIN
-25.38%
EBITDA MARGIN AVG TTM
-2417.91%
EBITDA MARGIN AVG 3Y
-1794.30%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+98.95%
CURRENT VS 3Y AVG
+98.59%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Fulcrum Therapeutics, Inc.
Market Cap
$281.16M
EBITDA Margin
-25.38%
TTM Avg
-2417.91%
3Y Avg
-1794.30%
5Y Avg
N/A
Market Cap
$279.56M
EBITDA Margin
-1475.69%
TTM Avg
-1475.69%
3Y Avg
-2002.71%
5Y Avg
-1922.41%
Market Cap
$286.94M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$275.95M
EBITDA Margin
-13.37%
TTM Avg
-2.68%
3Y Avg
-19.85%
5Y Avg
-36.16%
Market Cap
$272.91M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$272.17M
EBITDA Margin
-2082.59%
TTM Avg
-1743.06%
3Y Avg
-1015.79%
5Y Avg
-806.48%
Market Cap
$292.07M
EBITDA Margin
-101.16%
TTM Avg
-95.97%
3Y Avg
-88.25%
5Y Avg
-69.69%
Market Cap
$259.30M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | $281.16M | -25.38% | -2417.91% | -1794.30% | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $279.56M | -1475.69% | -1475.69% | -2002.71% | -1922.41% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $285.16M | N/A | N/A | N/A | N/A |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $286.94M | N/A | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $275.95M | -13.37% | -2.68% | -19.85% | -36.16% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $272.91M | N/A | N/A | N/A | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $272.17M | -2082.59% | -1743.06% | -1015.79% | -806.48% |
| Standard BioTools Inc. (LAB)vs › | $292.07M | -101.16% | -95.97% | -88.25% | -69.69% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.30M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $258.48M | -768.62% | -551.06% | -374.75% | -290.29% |
Gross Margin
0.0%
EBITDA Margin
-25.4%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2024-06-30 | 66.09% |
| 2023-12-31 | -3155.45% |
| 2023-09-30 | -3545.32% |
| 2023-06-30 | -3036.93% |
| 2023-03-31 | -9279.32% |
| 2022-12-31 | -3997.37% |
| 2022-09-30 | -2007.10% |
| 2022-06-30 | -1783.16% |
| 2022-03-31 | -982.33% |
| 2021-12-31 | -453.50% |
| 2021-09-30 | -408.33% |
| 2021-06-30 | -433.92% |
| 2021-03-31 | -343.29% |
| 2020-12-31 | -403.64% |
| 2020-09-30 | -1003.79% |
| 2020-06-30 | -768.55% |
| 2020-03-31 | -2434.27% |
